News for Ascendis Pharma A/S (A1SN34.SA)

Ascendis Pharma's COACH Trial shows promising results for achondroplasia treatment with TransCon CNP and TransCon hGH. Treatment-naïve cohort achieved

”“ Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo ”“ Multiple benefits beyo

SKYTROFA® (lonapegsomatropin) receives Therapeutic Goods Administration (TGA) approval in Australia for addressing pediatric growth hormone deficiency (GH

Below is the April 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update,

We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where Ascendis Pharma A/S (NASDAQ:ASND) stands against the ...

COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S ( ASND) today announced new data showing improvements in growth and bone morphometry

COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S ( ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial sho

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund’s Investor Class fund ARTMX returned -7.40%, Advisor Class fund APDMX posted a return of -7.37%, and Institutional Class fund APHMX returned -7.35%, compared […]

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ETCompany ParticipantsScott Smith - Executive Vice President and Chief...

COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S ( ASND) today announced it will report first quarter 2025 financial results and pr

**media[604994]**

\nAscendis Pharma represents 3.89% of the fund's total assets.Focuses on developing innovative therapies using its TransCon technology.Risks include clinical tri

BOSTON, April 15, 2025 /PRNewswire/ -- Below is the March 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE:ASG).

We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires.

The stock market has been on a rollercoaster ride for the past few weeks as the sentiment has quickly shifted from post-election bullishness to being priced in for a slow-down or a recession.

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S ( ASND) today announced that company executives will participate in a fireside chat

YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval SINGAPORE, Feb. 21, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH® (palopegteriparatide) by the Therapeutic Goods Administration (TGA), 'for the treatment of chronic hypoparathyroidism in adults'.1,2 YORVIPATH was granted an Orphan Drug Designation and assessed through the TGA's Priority Review pathway.3,4 It is the first and only medicine to be listed on the Australian Register of Therapeutic Goods (ARTG) for the treatment of chronic hypoparathyroidism.

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ETCompany ParticipantsScott Smith - Chief Financial OfficerJan...